Myelodysplastic Syndromes (MDS) research hub

A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)

This study looks at a new combination treatment, venetoclax and azacitidine, for people in the UK with a higher-risk type of blood cancer called Myelodysplastic Syndromes (MDS) who haven't had treatment before. It's an early-stage study to find the best dose.

A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

This study looks at the long-term safety of a medicine called luspatercept for people with certain blood disorders. It's for those already taking part in a luspatercept study to see if continuing the treatment is safe over a longer period.

Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation

This study looks at two medicines, ivosidenib and azacitidine, for a blood condition called myelodysplastic syndromes (MDS). It's for people with a specific gene change (IDH1 mutation) who haven't had certain treatments before. The aim is to see which medicine works best.

A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)

A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects with Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS)